Swedbank AB Takes Position in Olema Pharmaceuticals, Inc. $OLMA

Swedbank AB bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 55,100 shares of the company’s stock, valued at approximately $1,378,000.

A number of other large investors have also recently bought and sold shares of the business. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in Olema Pharmaceuticals during the 4th quarter worth $88,000. EverSource Wealth Advisors LLC boosted its stake in Olema Pharmaceuticals by 9,476.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after purchasing an additional 1,232 shares during the period. Legato Capital Management LLC acquired a new stake in Olema Pharmaceuticals during the 4th quarter worth $289,000. PSP Research LLC acquired a new stake in Olema Pharmaceuticals during the 4th quarter worth $477,000. Finally, ProShare Advisors LLC boosted its stake in Olema Pharmaceuticals by 13.8% during the 4th quarter. ProShare Advisors LLC now owns 14,367 shares of the company’s stock worth $359,000 after purchasing an additional 1,740 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

Wall Street Analyst Weigh In

OLMA has been the subject of a number of recent research reports. Oppenheimer reiterated an “outperform” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. Stifel Nicolaus initiated coverage on shares of Olema Pharmaceuticals in a research note on Wednesday, February 11th. They set a “buy” rating and a $48.00 price target for the company. Wolfe Research initiated coverage on shares of Olema Pharmaceuticals in a research note on Friday, March 27th. They set a “peer perform” rating for the company. TD Cowen reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. Finally, Wall Street Zen upgraded shares of Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, April 27th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $44.10.

Olema Pharmaceuticals Stock Down 4.7%

Shares of Olema Pharmaceuticals stock opened at $12.91 on Thursday. The company has a market cap of $1.13 billion, a P/E ratio of -6.39 and a beta of 2.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.88 and a current ratio of 10.88. Olema Pharmaceuticals, Inc. has a one year low of $3.89 and a one year high of $36.26. The firm has a fifty day moving average of $14.79 and a two-hundred day moving average of $20.81.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, hitting analysts’ consensus estimates of ($0.52). On average, analysts forecast that Olema Pharmaceuticals, Inc. will post -2.16 earnings per share for the current year.

Insider Buying and Selling

In other Olema Pharmaceuticals news, insider Shawnte Mitchell sold 25,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total transaction of $606,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 12.56% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.